 | • レポートコード：GIR-105X12184 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、89ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、多発性硬化症治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。多発性硬化症治療薬の種類別市場規模（注射薬、経口薬、その他）、用途別市場規模（大人、子供）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・多発性硬化症治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Biogen、Sanofi、Novartis、Teva、Merck KGaA、Bayer、ACORDA、Mallinckrodt ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：注射薬、経口薬、その他 ・用途別分析2016年-2026年：大人、子供 ・多発性硬化症治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・多発性硬化症治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・多発性硬化症治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・多発性硬化症治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・多発性硬化症治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Multiple Sclerosis Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Multiple Sclerosis Drugs size is estimated to be xx million in 2021 from USD 15030 million in 2020, with a change of XX% between 2020 and 2021. The global Multiple Sclerosis Drugs market size is expected to grow at a CAGR of 4.8% for the next five years.
Market segmentation
Multiple Sclerosis Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Injectable Medications
Oral Medications
Others
Market segment by Application can be divided into
Adults
Children
The key market players for global Multiple Sclerosis Drugs market are listed below:
Biogen
Sanofi
Novartis
Teva
Merck KGaA
Bayer
ACORDA
Mallinckrodt
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Multiple Sclerosis Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Multiple Sclerosis Drugs, with price, sales, revenue and global market share of Multiple Sclerosis Drugs from 2019 to 2021.
Chapter 3, the Multiple Sclerosis Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Multiple Sclerosis Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Multiple Sclerosis Drugs market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Multiple Sclerosis Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Multiple Sclerosis Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Multiple Sclerosis Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Injectable Medications
1.2.3 Oral Medications
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Multiple Sclerosis Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Adults
1.3.3 Children
1.4 Global Multiple Sclerosis Drugs Market Size & Forecast
1.4.1 Global Multiple Sclerosis Drugs Sales in Value (2016-2026))
1.4.2 Global Multiple Sclerosis Drugs Sales in Volume (2016-2026)
1.4.3 Global Multiple Sclerosis Drugs Price by Type (2016-2026) & (USD/Unit)
1.5 Global Multiple Sclerosis Drugs Production Capacity Analysis
1.5.1 Global Multiple Sclerosis Drugs Total Production Capacity (2016-2026)
1.5.2 Global Multiple Sclerosis Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Multiple Sclerosis Drugs Market Drivers
1.6.2 Multiple Sclerosis Drugs Market Restraints
1.6.3 Multiple Sclerosis Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Biogen
2.1.1 Biogen Details
2.1.2 Biogen Major Business
2.1.3 Biogen Multiple Sclerosis Drugs Product and Services
2.1.4 Biogen Multiple Sclerosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Multiple Sclerosis Drugs Product and Services
2.2.4 Sanofi Multiple Sclerosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Multiple Sclerosis Drugs Product and Services
2.3.4 Novartis Multiple Sclerosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Teva
2.4.1 Teva Details
2.4.2 Teva Major Business
2.4.3 Teva Multiple Sclerosis Drugs Product and Services
2.4.4 Teva Multiple Sclerosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Merck KGaA
2.5.1 Merck KGaA Details
2.5.2 Merck KGaA Major Business
2.5.3 Merck KGaA Multiple Sclerosis Drugs Product and Services
2.5.4 Merck KGaA Multiple Sclerosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Bayer
2.6.1 Bayer Details
2.6.2 Bayer Major Business
2.6.3 Bayer Multiple Sclerosis Drugs Product and Services
2.6.4 Bayer Multiple Sclerosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 ACORDA
2.7.1 ACORDA Details
2.7.2 ACORDA Major Business
2.7.3 ACORDA Multiple Sclerosis Drugs Product and Services
2.7.4 ACORDA Multiple Sclerosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Mallinckrodt
2.8.1 Mallinckrodt Details
2.8.2 Mallinckrodt Major Business
2.8.3 Mallinckrodt Multiple Sclerosis Drugs Product and Services
2.8.4 Mallinckrodt Multiple Sclerosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Multiple Sclerosis Drugs Sales by Manufacturer
3.1 Global Multiple Sclerosis Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Multiple Sclerosis Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Multiple Sclerosis Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Multiple Sclerosis Drugs Manufacturer Market Share
3.4.2 Top 6 Multiple Sclerosis Drugs Manufacturer Market Share
3.5 Global Multiple Sclerosis Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Multiple Sclerosis Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Multiple Sclerosis Drugs Market Size by Region
4.1.1 Global Multiple Sclerosis Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Multiple Sclerosis Drugs Revenue by Region (2016-2026)
4.2 North America Multiple Sclerosis Drugs Revenue (2016-2026)
4.3 Europe Multiple Sclerosis Drugs Revenue (2016-2026)
4.4 Asia-Pacific Multiple Sclerosis Drugs Revenue (2016-2026)
4.5 South America Multiple Sclerosis Drugs Revenue (2016-2026)
4.6 Middle East and Africa Multiple Sclerosis Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Multiple Sclerosis Drugs Sales in Volume by Type (2016-2026)
5.2 Global Multiple Sclerosis Drugs Revenue by Type (2016-2026)
5.3 Global Multiple Sclerosis Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Multiple Sclerosis Drugs Sales in Volume by Application (2016-2026)
6.2 Global Multiple Sclerosis Drugs Revenue by Application (2016-2026)
6.3 Global Multiple Sclerosis Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Multiple Sclerosis Drugs Sales by Type (2016-2026)
7.2 North America Multiple Sclerosis Drugs Sales by Application (2016-2026)
7.3 North America Multiple Sclerosis Drugs Market Size by Country
7.3.1 North America Multiple Sclerosis Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Multiple Sclerosis Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Multiple Sclerosis Drugs Sales by Type (2016-2026)
8.2 Europe Multiple Sclerosis Drugs Sales by Application (2016-2026)
8.3 Europe Multiple Sclerosis Drugs Market Size by Country
8.3.1 Europe Multiple Sclerosis Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Multiple Sclerosis Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Multiple Sclerosis Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Multiple Sclerosis Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Multiple Sclerosis Drugs Market Size by Region
9.3.1 Asia-Pacific Multiple Sclerosis Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Multiple Sclerosis Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Multiple Sclerosis Drugs Sales by Type (2016-2026)
10.2 South America Multiple Sclerosis Drugs Sales by Application (2016-2026)
10.3 South America Multiple Sclerosis Drugs Market Size by Country
10.3.1 South America Multiple Sclerosis Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Multiple Sclerosis Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Multiple Sclerosis Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Multiple Sclerosis Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Multiple Sclerosis Drugs Market Size by Country
11.3.1 Middle East & Africa Multiple Sclerosis Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Multiple Sclerosis Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Multiple Sclerosis Drugs Typical Distributors
12.3 Multiple Sclerosis Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Multiple Sclerosis Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Multiple Sclerosis Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. Biogen Basic Information, Manufacturing Base and Competitors
Table 4. Biogen Major Business
Table 5. Biogen Multiple Sclerosis Drugs Product and Services
Table 6. Biogen Multiple Sclerosis Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Sanofi Basic Information, Manufacturing Base and Competitors
Table 8. Sanofi Major Business
Table 9. Sanofi Multiple Sclerosis Drugs Product and Services
Table 10. Sanofi Multiple Sclerosis Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Novartis Basic Information, Manufacturing Base and Competitors
Table 12. Novartis Major Business
Table 13. Novartis Multiple Sclerosis Drugs Product and Services
Table 14. Novartis Multiple Sclerosis Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Teva Basic Information, Manufacturing Base and Competitors
Table 16. Teva Major Business
Table 17. Teva Multiple Sclerosis Drugs Product and Services
Table 18. Teva Multiple Sclerosis Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 20. Merck KGaA Major Business
Table 21. Merck KGaA Multiple Sclerosis Drugs Product and Services
Table 22. Merck KGaA Multiple Sclerosis Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Bayer Basic Information, Manufacturing Base and Competitors
Table 24. Bayer Major Business
Table 25. Bayer Multiple Sclerosis Drugs Product and Services
Table 26. Bayer Multiple Sclerosis Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. ACORDA Basic Information, Manufacturing Base and Competitors
Table 28. ACORDA Major Business
Table 29. ACORDA Multiple Sclerosis Drugs Product and Services
Table 30. ACORDA Multiple Sclerosis Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Mallinckrodt Basic Information, Manufacturing Base and Competitors
Table 32. Mallinckrodt Major Business
Table 33. Mallinckrodt Multiple Sclerosis Drugs Product and Services
Table 34. Mallinckrodt Multiple Sclerosis Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Global Multiple Sclerosis Drugs Sales by Manufacturer (2019-2021e) & (K Units)
Table 36. Global Multiple Sclerosis Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 37. Market Position of Manufacturers in Multiple Sclerosis Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 38. Global Multiple Sclerosis Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 39. Head Office and Multiple Sclerosis Drugs Production Site of Key Manufacturer
Table 40. Multiple Sclerosis Drugs New Entrant and Capacity Expansion Plans
Table 41. Multiple Sclerosis Drugs Mergers & Acquisitions in the Past Five Years
Table 42. Global Multiple Sclerosis Drugs Sales by Region (2016-2021e) & (K Units)
Table 43. Global Multiple Sclerosis Drugs Sales by Region (2021-2026) & (K Units)
Table 44. Global Multiple Sclerosis Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 45. Global Multiple Sclerosis Drugs Revenue by Region (2021-2026) & (USD Million)
Table 46. Global Multiple Sclerosis Drugs Sales by Type (2016-2021e) & (K Units)
Table 47. Global Multiple Sclerosis Drugs Sales by Type (2021-2026) & (K Units)
Table 48. Global Multiple Sclerosis Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 49. Global Multiple Sclerosis Drugs Revenue by Type (2021-2026) & (USD Million)
Table 50. Global Multiple Sclerosis Drugs Price by Type (2016-2021e) & (USD/Unit)
Table 51. Global Multiple Sclerosis Drugs Price by Type (2021-2026) & (USD/Unit)
Table 52. Global Multiple Sclerosis Drugs Sales by Application (2016-2021e) & (K Units)
Table 53. Global Multiple Sclerosis Drugs Sales by Application (2021-2026) & (K Units)
Table 54. Global Multiple Sclerosis Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 55. Global Multiple Sclerosis Drugs Revenue by Application (2021-2026) & (USD Million)
Table 56. Global Multiple Sclerosis Drugs Price by Application (2016-2021e) & (USD/Unit)
Table 57. Global Multiple Sclerosis Drugs Price by Application (2021-2026) & (USD/Unit)
Table 58. North America Multiple Sclerosis Drugs Sales by Country (2016-2021e) & (K Units)
Table 59. North America Multiple Sclerosis Drugs Sales by Country (2021-2026) & (K Units)
Table 60. North America Multiple Sclerosis Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 61. North America Multiple Sclerosis Drugs Revenue by Country (2021-2026) & (USD Million)
Table 62. North America Multiple Sclerosis Drugs Sales by Type (2016-2021e) & (K Units)
Table 63. North America Multiple Sclerosis Drugs Sales by Type (2021-2026) & (K Units)
Table 64. North America Multiple Sclerosis Drugs Sales by Application (2016-2021e) & (K Units)
Table 65. North America Multiple Sclerosis Drugs Sales by Application (2021-2026) & (K Units)
Table 66. Europe Multiple Sclerosis Drugs Sales by Country (2016-2021e) & (K Units)
Table 67. Europe Multiple Sclerosis Drugs Sales by Country (2021-2026) & (K Units)
Table 68. Europe Multiple Sclerosis Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 69. Europe Multiple Sclerosis Drugs Revenue by Country (2021-2026) & (USD Million)
Table 70. Europe Multiple Sclerosis Drugs Sales by Type (2016-2021e) & (K Units)
Table 71. Europe Multiple Sclerosis Drugs Sales by Type (2021-2026) & (K Units)
Table 72. Europe Multiple Sclerosis Drugs Sales by Application (2016-2021e) & (K Units)
Table 73. Europe Multiple Sclerosis Drugs Sales by Application (2021-2026) & (K Units)
Table 74. Asia-Pacific Multiple Sclerosis Drugs Sales by Region (2016-2021e) & (K Units)
Table 75. Asia-Pacific Multiple Sclerosis Drugs Sales by Region (2021-2026) & (K Units)
Table 76. Asia-Pacific Multiple Sclerosis Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 77. Asia-Pacific Multiple Sclerosis Drugs Revenue by Region (2021-2026) & (USD Million)
Table 78. Asia-Pacific Multiple Sclerosis Drugs Sales by Type (2016-2021e) & (K Units)
Table 79. Asia-Pacific Multiple Sclerosis Drugs Sales by Type (2021-2026) & (K Units)
Table 80. Asia-Pacific Multiple Sclerosis Drugs Sales by Application (2016-2021e) & (K Units)
Table 81. Asia-Pacific Multiple Sclerosis Drugs Sales by Application (2021-2026) & (K Units)
Table 82. South America Multiple Sclerosis Drugs Sales by Country (2016-2021e) & (K Units)
Table 83. South America Multiple Sclerosis Drugs Sales by Country (2021-2026) & (K Units)
Table 84. South America Multiple Sclerosis Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 85. South America Multiple Sclerosis Drugs Revenue by Country (2021-2026) & (USD Million)
Table 86. South America Multiple Sclerosis Drugs Sales by Type (2016-2021e) & (K Units)
Table 87. South America Multiple Sclerosis Drugs Sales by Type (2021-2026) & (K Units)
Table 88. South America Multiple Sclerosis Drugs Sales by Application (2016-2021e) & (K Units)
Table 89. South America Multiple Sclerosis Drugs Sales by Application (2021-2026) & (K Units)
Table 90. Middle East & Africa Multiple Sclerosis Drugs Sales by Country (2016-2021e) & (K Units)
Table 91. Middle East & Africa Multiple Sclerosis Drugs Sales by Country (2021-2026) & (K Units)
Table 92. Middle East & Africa Multiple Sclerosis Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 93. Middle East & Africa Multiple Sclerosis Drugs Revenue by Country (2021-2026) & (USD Million)
Table 94. Middle East & Africa Multiple Sclerosis Drugs Sales by Type (2016-2021e) & (K Units)
Table 95. Middle East & Africa Multiple Sclerosis Drugs Sales by Type (2021-2026) & (K Units)
Table 96. Middle East & Africa Multiple Sclerosis Drugs Sales by Application (2016-2021e) & (K Units)
Table 97. Middle East & Africa Multiple Sclerosis Drugs Sales by Application (2021-2026) & (K Units)
Table 98. Direct Channel Pros & Cons
Table 99. Indirect Channel Pros & Cons
Table 100. Multiple Sclerosis Drugs Typical Distributors
Table 101. Multiple Sclerosis Drugs Typical Customers
List of Figures
Figure 1. Multiple Sclerosis Drugs Picture
Figure 2. Global Multiple Sclerosis Drugs Sales Market Share by Type in 2020
Figure 3. Injectable Medications
Figure 4. Oral Medications
Figure 5. Others
Figure 6. Global Multiple Sclerosis Drugs Sales Market Share by Application in 2020
Figure 7. Adults
Figure 8. Children
Figure 9. Global Multiple Sclerosis Drugs Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 10. Global Multiple Sclerosis Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 11. Global Multiple Sclerosis Drugs Sales (2016-2026) & (K Units)
Figure 12. Global Multiple Sclerosis Drugs Price by Type (2016-2026) & (USD/Unit)
Figure 13. Global Multiple Sclerosis Drugs Production Capacity (2016-2026) & (K Units)
Figure 14. Global Multiple Sclerosis Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 15. Multiple Sclerosis Drugs Market Drivers
Figure 16. Multiple Sclerosis Drugs Market Restraints
Figure 17. Multiple Sclerosis Drugs Market Trends
Figure 18. Global Multiple Sclerosis Drugs Sales Market Share by Manufacturer in 2020
Figure 19. Global Multiple Sclerosis Drugs Revenue Market Share by Manufacturer in 2020
Figure 20. Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. Top 3 Multiple Sclerosis Drugs Manufacturer (Revenue) Market Share in 2020
Figure 22. Top 6 Multiple Sclerosis Drugs Manufacturer (Revenue) Market Share in 2020
Figure 23. Global Multiple Sclerosis Drugs Sales Market Share by Region (2016-2026)
Figure 24. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2016-2026)
Figure 25. North America Multiple Sclerosis Drugs Revenue (2016-2026) & (USD Million)
Figure 26. Europe Multiple Sclerosis Drugs Revenue (2016-2026) & (USD Million)
Figure 27. Asia-Pacific Multiple Sclerosis Drugs Revenue (2016-2026) & (USD Million)
Figure 28. South America Multiple Sclerosis Drugs Revenue (2016-2026) & (USD Million)
Figure 29. Middle East & Africa Multiple Sclerosis Drugs Revenue (2016-2026) & (USD Million)
Figure 30. Global Multiple Sclerosis Drugs Sales Market Share by Type (2016-2026)
Figure 31. Global Multiple Sclerosis Drugs Revenue Market Share by Type (2016-2026)
Figure 32. Global Multiple Sclerosis Drugs Price by Type (2016-2026) & (USD/Unit)
Figure 33. Global Multiple Sclerosis Drugs Sales Market Share by Application (2016-2026)
Figure 34. Global Multiple Sclerosis Drugs Revenue Market Share by Application (2016-2026)
Figure 35. Global Multiple Sclerosis Drugs Price by Application (2016-2026) & (USD/Unit)
Figure 36. North America Multiple Sclerosis Drugs Sales Market Share by Type (2016-2026)
Figure 37. North America Multiple Sclerosis Drugs Sales Market Share by Application (2016-2026)
Figure 38. North America Multiple Sclerosis Drugs Sales Market Share by Country (2016-2026)
Figure 39. North America Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2026)
Figure 40. United States Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Canada Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Mexico Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Europe Multiple Sclerosis Drugs Sales Market Share by Type (2016-2026)
Figure 44. Europe Multiple Sclerosis Drugs Sales Market Share by Application (2016-2026)
Figure 45. Europe Multiple Sclerosis Drugs Sales Market Share by Country (2016-2026)
Figure 46. Europe Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2026)
Figure 47. Germany Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. France Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. United Kingdom Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Russia Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Italy Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Asia-Pacific Multiple Sclerosis Drugs Sales Market Share by Region (2016-2026)
Figure 53. Asia-Pacific Multiple Sclerosis Drugs Sales Market Share by Application (2016-2026)
Figure 54. Asia-Pacific Multiple Sclerosis Drugs Sales Market Share by Region (2016-2026)
Figure 55. Asia-Pacific Multiple Sclerosis Drugs Revenue Market Share by Region (2016-2026)
Figure 56. China Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Japan Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Korea Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. India Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Southeast Asia Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Australia Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South America Multiple Sclerosis Drugs Sales Market Share by Type (2016-2026)
Figure 63. South America Multiple Sclerosis Drugs Sales Market Share by Application (2016-2026)
Figure 64. South America Multiple Sclerosis Drugs Sales Market Share by Country (2016-2026)
Figure 65. South America Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East & Africa Multiple Sclerosis Drugs Sales Market Share by Type (2016-2026)
Figure 69. Middle East & Africa Multiple Sclerosis Drugs Sales Market Share by Application (2016-2026)
Figure 70. Middle East & Africa Multiple Sclerosis Drugs Sales Market Share by Country (2016-2026)
Figure 71. Middle East & Africa Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Egypt Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. South Africa Multiple Sclerosis Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
Figure 77. Methodology
Figure 78. Research Process and Data Source
多発性硬化症に対する幹細胞療法の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Multiple sclerosis is a nervous system disease, triggered by unidentified environmental factors that adversely affects the brain and spinal cord. It damages the myelin sheath that surrounds and protects the nerve cells. Some of the symptoms of the disease includes weakness, numbness, blurred vision,…- 多発性硬化症治療薬の世界市場2018-2025 Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the d…
- タイサブリ薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Tysabri (natalizumab) is a monoclonal antibody used in to treat relapsing forms of multiple sclerosis. Tysabri is also used to treat moderate to severe Crohn's disease in adults. Tysabri is usually given after other Crohn's disease medications have been tried without successful treatment of this con…
- 世界の多発性骨髄腫治療薬市場 2021：企業別、地域別、種類・用途別 The Multiple Myeloma Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulati…
- 自己免疫薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Abnormal immune responses of the innate immune system can cause autoimmune diseases, which can damage body tissues and lead to abnormal organ functions. Immunological complications due to physiological processes within the human body lead to autoimmune diseases. These diseases are characterized by c…